Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program

The comparative efficacy of alendronate, risedronate, denosumab and zoledronic acid in reducing fragility fracture risk has been demonstrated in more than one meta-analysis including only randomized clinical trials. The persistence rate and the level of compliance with treatment with alendronate or risedronate were, however, insufficient for real-world usage situations. These two conditions, which are essential for the efficacy of a given pharmacological treatment, had not been evaluated until now in regular users of denosumab or zoledronic acid..

The objectives of this study were to describe new users of alendronate, risedronate, denosumab or zoledronic acid and to assess the persistence rate and the level of compliance with these pharmacological therapies as well as with concomitantly administered calcium and vitamin D supplements.